Disc Medicine annual stock-based compensation
2020
2021
2022
2023
2024
2025
Disc Medicine Stock-Based Compensation Growth & History (IRON)
Disc Medicine's stock-based compensation was $34.3M for fiscal 2025.
View full Disc Medicine company overviewDisc Medicine annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $34.3M | $17.5M | +104.22% |
| 2024 | 2024-12-31 | $16.8M | $11.3M | +204.07% |
| 2023 | 2023-12-31 | $5.5M | $3.4M | +164.72% |
| 2022 | 2022-12-31 | $2.1M | $1.6M | +312.03% |
| 2021 | 2021-12-31 | $507,000 | −$476,000 | −48.42% |
| 2020 | 2020-12-31 | $983,000 | — | — |
Disc Medicine quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.9M | $5.5M | +65.65% |
| Q1 2026 | 2026-03-31 | $11.9M | $5.6M | +87.74% |
| Q4 2025 | 2025-12-31 | $10.0M | $5.7M | +131.73% |
| Q3 2025 | 2025-09-30 | $9.5M | $5.2M | +119.62% |
| Q2 2025 | 2025-06-30 | $8.4M | $4.3M | +105.82% |
| Q1 2025 | 2025-03-31 | $6.4M | $2.3M | +56.80% |
| Q4 2024 | 2024-12-31 | $4.3M | $2.4M | +124.91% |
| Q3 2024 | 2024-09-30 | $4.3M | $3.1M | +241.10% |
| Q2 2024 | 2024-06-30 | $4.1M | $2.8M | +212.53% |
| Q1 2024 | 2024-03-31 | $4.1M | $3.0M | +296.29% |
| Q4 2023 | 2023-12-31 | $1.9M | $934,000 | +94.06% |
| Q3 2023 | 2023-09-30 | $1.3M | $888,000 | +232.46% |
| Q2 2023 | 2023-06-30 | $1.3M | $927,000 | +242.67% |
| Q1 2023 | 2023-03-31 | $1.0M | $692,000 | +208.43% |
| Q4 2022 | 2022-12-31 | $993,000 | — | — |
| Q3 2022 | 2022-09-30 | $382,000 | −$1.3M | −76.97% |
| Q2 2022 | 2022-06-30 | $382,000 | −$2.5M | −86.65% |
| Q1 2022 | 2022-03-31 | $332,000 | −$1.3M | −79.16% |
| Q3 2021 | 2021-09-30 | $1.7M | $1.5M | +930.43% |
| Q2 2021 | 2021-06-30 | $2.9M | $2.7M | +1973.91% |
| Q1 2021 | 2021-03-31 | $1.6M | $1.5M | +1594.68% |
| Q4 2020 | 2020-12-31 | $590,000 | — | — |
| Q3 2020 | 2020-09-30 | $161,000 | — | — |
| Q2 2020 | 2020-06-30 | $138,000 | — | — |
| Q1 2020 | 2020-03-31 | $94,000 | — | — |
Disc Medicine stock-based compensation trends
Over the last five fiscal years, Disc Medicine's stock-based compensation increased from $983,000 to $34.3M, a change of $33.4M. The latest reported quarter, Q2 2026, shows $13.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Disc Medicine source filings ↗